Investors turn to pharma for yields

Everyone is looking for a safer place to put their money these days, and that means analysts and stock-pickers are paying closer attention to Big Pharma. Traditionally, drug stocks are seen as a "recession-proof" play, and though we've recently covered news of cash-strapped patients cutting back on their medications, those folks aren't likely to scrimp as much at the pharmacy as they will at Macy's and Target and Lowe's.

Plus, as Seeking Alpha points out today, drug stocks also pay dividends. Here's a list of that site's top 10 pharma picks, each with P/E's below 20 and a price-to-earnings-to-growth (PEG) of less than three.

  • Pfizer is famous for its dividend. It's the highest-yielding stock on this list, at 7.5 percent with a P/E of 12.7 and PEG of 2.12.
  • Bristol-Myers Squibb yields 7.2 percent, with a P/E of 16.3 and PEG of 1.54.
  • GlaxoSmithKline boasts a yield of 5.5 percent, with a P/E of 11.9 and PEG of 1.99.
  • Eli Lilly also yields 5.5 percent, and its P/E is a low 9.9; PEG stands at 1.39.
  • Merck stock now yields 5.4 percent; its P/E is 12.4 and PEG is 2.48.
  • Bayer's yield is a big dropoff from Merck's at 3.8 percent; its P/E is 13.2 and PEG is 1.26.
  • Wyeth yields 3.5 percent, with a low low P/E of 9.6 and PEG of 2.48.
  • Roche yields 3.3 percent, and its P/E is 14.6. PEG is 1.91.
  • Novartis yields almost as much, at 3.2 percent, and its P/E is 16. PEG is 2.34.
  • Johnson & Johnson's yield stands at 2.9 percent, with a P/E of 14.4 and PEG of 1.65.

- read the story at Seeking Alpha

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.